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Abstract
Objective. This was an exploratory analysis to develop a new way of representing BILAG-2004 system
scores longitudinally that would be clinically meaningful and easier to analyse in comparison with multiple
categorical variables.
Methods. Data from a multicentre longitudinal study of SLE patients (the BILAG-2004 index and therapy
collected at every visit) were used. External responsiveness analysis of the index suggested the possibility
of using counts of systems with specified transitions in scores as a basis to analyse the system scores.
Exploratory analyses with multinomial logistic regression were used to examine the appropriateness of this
new method of analysing BILAG-2004 system scores. Receiver operating characteristic (ROC) curve ana-
lysis was used to assess the performance of this approach.
Results. There were 1414 observations from 347 patients. A novel method was devised based on counts
of systems with defined transitions in score (BILAG-2004 systems tally, BST). It has six components
(systems with major deterioration, systems with minor deterioration, systems with persistent significant
activity, systems with major improvement, systems with minor improvement and systems with persistent
minimal or no activity). This was further simplified (simplified BST, sBST) into three components
(systems with active/worsening disease, systems with improving disease and systems with persistent
minimal or no activity). Both versions had expected associations with change in therapy. ROC curve
analyses demonstrated that both versions had similar good performance characteristics (areas under
the curve >0.80) in predicting increase in therapy.
Conclusion. The BST and sBST provide alternative approaches to representing BILAG-2004 disease
activity longitudinally. Further validation of their use is required.
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Introduction
The BILAG-2004 index is a system-based disease activity
index that has been validated for SLE and is one of the
recommended disease activity outcome measures used in
clinical trials of SLE [14]. This index provides disease
activity scores across nine systems using an ordinal
scale score (from A to E). Although this is clinically intui-
tive, the analysis of nine separate system scores poses a
great challenge in clinical studies. The development of a
global numerical scoring for the BILAG-2004 index offers
one approach to overcome the difficulty with analysis, but
it is hampered by the difficulty in interpretation of its clin-
ically meaningful change [5].
Currently, most analyses of the classic BILAG or
BILAG-2004 index scores are based on categorization of
the outcome variable, especially dichotomization into a
binary (yes/no) response. In the rituximab EXPLORER
trial, the outcome end points were major clinical response,
partial clinical response or no response [6]. Furthermore,
the criteria for the clinical responses were based on
dichotomization of whether certain classic BILAG scores
were achieved and maintained. Similarly the combinations
of indices used in the belimumab and epratuzumab trials
are also based on dichotomization of responses [7, 8].
However, dichotomization of variables does not allow the
gradation of response according to severity to be taken
into account in the analysis. It is potentially worthwhile
capturing the amount of improvement or worsening in dif-
ferent systems, particularly over time. A drug that induced
improvement in more systems than another would then be
more easily recognized as doing so. This is essentially
why, from a technical point of view, dichotomization of
variables results in loss of efficiency [9]. In addition, there
is difficulty in accounting for all the changes in disease
activity occurring between the beginning and end of a
study. It has to be borne in mind that prolonged remission
is uncommon in the context of clinical trials of SLE, and
changes in disease activity in both directions (improve-
ment and worsening) may occur concomitantly across dif-
ferent systems. Although a numerical score is able to
capture this globally, it is not possible to identify how
changes in disease activity occurred across different
systems.
The ideal solution would be a representation of the
BILAG-2004 system scores that is clinically relevant and
meaningful that allows for the gradation of response ac-
cording to severity, avoids dichotomization and takes into
consideration the categorical nature of the data.
Furthermore, it has to be relatively easy to analyse as
compared with categorical data. Using these principles,
we performed exploratory analyses on the data from a
large longitudinal study of SLE patients seen in routine
clinical practice. Based on our analysis, we propose a
novel way of representing the BILAG-2004 index scores
longitudinally in clinical studies, especially for clinical
trials. This new method captures the total number of sys-
tems with defined transitions in disease activity (reflecting
improvement, worsening or persistence) that can be
analysed as a single observation (between two assess-
ments) or cumulatively over time.
Patients and methods
Data from a multicentre longitudinal study in the UK that
was primarily designed to validate the BILAG-2004 index
were used in the analysis [4]. All patients satisfied the
revised ACR criteria for classification of SLE [10, 11].
Patients were excluded from the study if they were preg-
nant, aged <18 years or unable to give valid consent. The
original study to which this study is an additional analysis
received ethics approval (Hull and East Riding Research
Ethics Committee) and was carried out in accordance with
the Declaration of Helsinki. Written consent was obtained
from all patients.
This study has been described in detail previously [4].
In summary, patients were followed up prospectively and
data (BILAG-2004 index and treatment) were collected for
all consecutive visits or encounters that the patients had
with the physician. For this analysis, changes in disease
activity and treatment between two consecutive visits
were studied. A robust definition for change in therapy
between consecutive visits was used as the external ref-
erence for change in disease activity. This definition
has been described previously [4] and is available as sup-
plementary data (Section A), available at Rheumatology
Online. Three categories of changes in therapy were
defined as follows: no change, increase in therapy and
decrease in therapy.
Statistical analysis
Exploratory analyses were performed using external
responsiveness methodology [12]. It assesses the extent
to which changes in the index over time relate to corres-
ponding changes in therapy (external reference) between
two consecutive visits. Therefore each observation for the
analysis was derived from two consecutive visits.
Initially, maximum-likelihood multinomial logistic regres-
sion was used to assess external responsiveness, with
change in therapy as the outcome variable and changes
in disease activity (according to the index) as the explana-
tory variables. This methodology essentially fits two binary
logistic regression models. The first discriminates be-
tween increases in therapy and no change in therapy
between visits, with no change in therapy being regarded
as the baseline category. The second discriminates be-
tween decreases in therapy and no change in therapy.
Explanatory variables are defined based on changes in
disease activity, with minimal change in activity taken as
the reference category. Thus the association between
change in disease activity and change in therapy was as-
sessed in both directions (increase and decrease). The
comparison between increase in therapy and decrease
in therapy is implicit in this model and is not directly esti-
mated. The results were reported as coefficients, with
95% CI. A coefficient value >0 for a particular change in
score within the comparison between increase in therapy
and no change in therapy indicates that the change in
score is associated with increase in therapy. Conversely,
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a negative coefficient value (<0) for a particular change in
score within the comparison between increase in therapy
and no change in therapy indicates that the change in
score is associated with no change in therapy (and not
with decrease in therapy) or equivalently an inverse asso-
ciation with increase in therapy. This interpretation applies
similarly to the comparison between decrease in therapy
and no change in therapy.
In particular, we devised a new method of classifying
changes in the BILAG-2004 system scores, and the ap-
propriateness of this scheme was assessed using the ex-
ternal responsiveness analysis. In addition, receiver
operating characteristic (ROC) curve analysis was used
to describe the performance of the various models for
representing the BILAG-2004 index scores [13]. For this
purpose, areas under the curve (AUC) were estimated
from relevant logistic regression models. One model
focused on the analysis of increase in therapy (indicating
deterioration in disease activity) versus no change in ther-
apy, and another model focused on increase in therapy
versus no increase in therapy (combination of no change
in therapy and decrease in therapy). Similarly two models
were fitted to focus on decrease in therapy (indicating
improvement in disease activity) versus no change in ther-
apy and decrease in therapy versus no decrease in ther-
apy (combination of no change in therapy and increase in
therapy).
All statistical analyses were performed using Stata for
Windows version 8 (StataCorp, College Station, TX, USA)
and R [14]. Robust variance estimation was used in the
analyses to accommodate multiple assessments from the
same patients [15].
Results
There were 347 SLE patients (92.9% female patients,
57.9% Caucasian, 20.5% AfroCaribbean and 19%
South Asian) with 1761 assessments that contributed
1414 observations for analysis (demographics summar-
ized in supplementary Table B, available at
Rheumatology Online). The median duration of follow-up
was 11 months (range 126 months). Increase in treat-
ment between consecutive visits occurred in 22.7% of
observations, while 37.3% of observations had therapy
decreased, and in 40% of observations there was no
change in treatment. The distribution of changes in dis-
ease activity according to BILAG-2004 and change in
therapy is available as supplementary Table C, available
at Rheumatology Online.
Development of BILAG-2004 systems tally
Based on the external responsiveness of the changes in
the BILAG-2004 index system scores [4], we devised a
new method of classifying changes in the BILAG-2004
index system scores, using counts of systems with spe-
cified transitions in scores. It records the number of sys-
tems in which activity increased, decreased or remained
the same between two consecutive visits and expresses
this as a tally (BILAG-2004 systems tally, BST). It has the
following six components:
(i) Number of systems with major deterioration
(change from grade B/C/D/E to A or grade D/E
to B).
(ii) Number of systems with minor deterioration
(change from grade C to B).
(iii) Number of systems with persistent significant activ-
ity (no change from grade A or B).
(iv) Number of systems with major improvement
(change from grade A to C/D or grade B to D).
(v) Number of systems with minor improvement
(change from grade A to B or grade B to C).
(vi) Number of systems with persistent minimal or no
activity (change from grade C/D/E to C/D/E).
This was further simplified into three components (sim-
plified BILAG-2004 systems tally, sBST) by grouping
major deterioration, minor deterioration and persistent
activity into a single group, and major improvement with
minor improvement into another group:
(i) Number of systems with active/worsening disease
(systems with major deterioration, minor deterior-
ation and persistent significant activity).
(ii) Number of systems with improving disease
(systems with major improvement and minor
improvement).
(iii) Number of systems with persistent minimal or no
activity.
Further details on the development of the BST and
sBST are available in the supplementary data (Section
B), available at Rheumatology Online. We examined both
these measures, as we did not wish to be limiting or pre-
scriptive in our investigation.
Assessment of BST and sBST
The external responsiveness analysis of BST demon-
strated that it was appropriate for use, as it had the
expected significant associations with change in therapy
(Table 1). The number of systems with major deterioration,
minor deterioration and persistent significant activity were
independently associated with increase in therapy. On the
other hand, the number of systems with major improve-
ment and minor improvement were independently asso-
ciated with decrease in therapy. Similarly the sBST was
shown to be appropriate for use, as the number of sys-
tems with active/worsening disease were independently
associated with increase in therapy, and the number of
systems with improving disease were independently
associated with decrease in therapy (Table 2). Table 3
summarizes the distribution of changes in therapy accord-
ing to the sBST components, and it has to be noted that
these components are not mutually exclusive.
A formal test of the linearity assumption for the sBST
components in Table 2 compared a model with five level
factor versions of each variable (corresponding to values of
0, 1, 2, 3 and 4) with the model of Table 2. This generated a
significance level of 0.42 (2 value of 12.3 on 12 degrees of
freedom). As there are few values of 4 in either variable, and
this creates some numerical instability, these were also
grouped with values of 3, and this led to a P-value of 0.23
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for a test of non-linearity (2 value of 10.5 on 8 degrees of
freedom). From this analysis, the estimated coefficients for
the factors corresponding to one system, two systems and
three or four systems with active/worsening disease were
2.4, 3.6 and 4.4 for the increase in therapy component of
the model. Comparable coefficients for the number of sys-
tems improving for the decrease in therapy component
were 0.62, 0.66, and 1.01.
Performance of BST and sBST
ROC curve analyses for BST and sBST are summarized
in Table 4, with other methods for analysing the
BILAG-2004 index scores included for comparative pur-
poses. For the BILAG-2004 numerical scoring [5], the
combination of change in numerical score and the nu-
merical score of the previous visit has superior perform-
ance to the single variable of just change in score, in a
TABLE 1 External responsiveness of the BST with multinomial logistic regression (n= 1414)
BSTa
Number of
observations
Increase in
therapyb coefficient
(95% CI)
Decrease in
therapyb coefficient
(95% CI)
Number of systems with major deteriorationc 2.82 (2.34, 3.30)d 0.22 (0.79, 0.35)
One system with major deterioration 144  
Two systems with major deterioration 23  
Three systems with major deterioration 3  
Number of systems with minor deteriorationc 1.88 (1.22, 2.55)d 0.02 (0.63, 0.59)
One system with deterioration 94  
Two systems with deterioration 9  
Number of systems with persistent significant activityc 1.64 (1.21, 2.06)d 0.38 (0.79, 0.03)
One system with persistent significant activity 166  
Two systems with persistent significant activity 11  
Three systems with persistent significant activity 2  
Number of systems with minor improvementc 0.28 (0.73, 0.17) 0.33 (0.04, 0.62)d
One system with improvement 158  
Two systems with improvement 23  
Three systems with improvement 7  
Number of systems with major improvementc 0.18 (0.26, 0.63) 0.56 (0.23, 0.89)d
One system with major improvement 150  
Two systems with major improvement 18  
Three systems with major improvement 5  
Number of systems with persistent minimal or no activityc 0 0
Five or fewer systems with persistent minimal or no activity 51  
Six systems with persistent minimal or no activity 144  
Seven systems with persistent minimal or no activity 441  
Eight or nine systems with persistent minimal or no activity 778  
aMajor deterioration: change of grade B/C/D/E to A or grade D/E to B. Minor deterioration: change of grade C to B. Persistent
significant activity: no change from grade A or B. Major improvement: change of grade A to C/D or grade B to D. Minor
improvement: change of grade A to B or grade B to C. Persistent minimal or no activity: change of grade C/D/E to C/D/E. bAs
compared with no change in therapy. cBreakdown of number of observations with the respective number of systems in each
of the BST components. dStatistically significant association.
TABLE 2 External responsiveness of the sBST with multinomial logistic regression (n= 1414)
sBSTa
Number of
non-zero
observations
Increase in
therapyb
coefficient
(95% CI)
Decrease in
therapyb
coefficient
(95% CI)
Number of systems with active/worsening disease 391 2.08 (1.72, 2.43)c 0.24 (0.58, 0.09)
Number of systems with improving disease 330 0.05 (0.39, 0.29) 0.43 (0.21, 0.65)c
Number of systems with persistent minimal or no activity 1414 0 0
aActive/worsening disease: systems with major deterioration, minor deterioration and persistent significant activity. Improving
disease: systems with major improvement and minor improvement. Persistent minimal or no activity: change of grade C/D/E to
C/D/E. bAs compared with no change in therapy. cStatistically significant association.
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similar fashion to SLEDAI-2000, which we have previ-
ously demonstrated [16]. BST and sBST performed
well, in particular with increase in therapy (indicating de-
terioration in disease activity), with an AUC >0.80. Apart
from the analysis using the original BILAG-2004 index
system scores (with nine categorical system scores)
and the single variable of change in BILAG-2004 numer-
ical score, all the other models for analysing the
BILAG-2004 index scores have similar performance
characteristics.
Table 4 is included to give a simple illustration of the
relative value of the different forms of the BILAG-2004
data, and formal statistical analyses are not presented.
Any particular weighted sums of the different components
of BST or sBST, and in particular the weightings derived
from the logistic regressions that underlie Table 4, are not
being advocated. In a clinical trial, treatment comparisons
would be based on relevant aspects of these tallies
(see Discussion). However, for indicative purposes, we
note that a 95% bootstrap CI for the AUC value of 0.83,
estimated for use of the BST when related to increase in
therapy versus no increase in therapy, is (0.81, 0.86).
Comparable intervals for the sBST and original BILAG-
2004 index system score values of 0.81 and 0.75 are
(0.78, 0.85) and (0.70, 0.78). This illustrates that the
precision of the estimated AUCs in Table 4 supports
the general conclusions drawn. In addition, because
the regression coefficients underlying the estimates in
TABLE 4 AUC values from ROC curve analysis of the different models of the BILAG-2004 index scores
Model
Increase in therapy Decrease in therapy
Versus no
change in
therapy
Versus no
increase in
therapy
Versus no
change in
therapy
Versus no
decrease in
therapy
Original BILAG-2004 index system
scores (nine separate changes in
system scores)
0.75 0.75 0.59 0.65
Counts of BILAG-2004 systems with
transition in scores
(as in supplementary Table C, avail-
able at Rheumatology Online)
0.85 0.86 0.59 0.68
BST (as in Table 2) 0.82 0.83 0.57 0.66
sBST (as in Table 3) 0.81 0.81 0.57 0.65
Change in BILAG-2004 numerical
score
0.73 0.75 0.58 0.65
BILAG-2004 numerical score variables
(change in numerical score and pre-
vious visit numerical score included
in model)
0.84 0.85 0.58 0.67
TABLE 3 Cross tabulation of the sBST with change in therapy (n= 1414)
sBSTa
Number of
observations
Increase
in therapy
(%)
No change
in therapy
(%)
Decrease in
therapy
(%)
Number of systems with active/worsening diseaseb
One system with active/worsening disease 295 155 (52.5) 77 (26.1) 63 (21.4)
Two systems with active/worsening disease 80 65 (81.3) 10 (12.5) 5 (6.3)
Three systems with active/worsening disease 14 13 (92.9) 1 (7.1) 0 (0)
Four systems with active/worsening disease 2 2 (100) 0 (0) 0 (0)
Number of systems with improving diseaseb
One system with improving disease 256 55 (21.5) 81 (31.6) 120 (46.9)
Two systems with improving disease 56 3 (5.4) 21 (37.5) 32 (57.1)
Three systems with improving disease 14 1 (7.1) 5 (35.7) 8 (57.1)
Four systems with improving disease 4 1 (25.0) 0 (0) 3 (75.0)
aActive/worsening disease: systems with major deterioration, minor deterioration and persistent significant activity. Improving
disease: systems with major improvement and minor improvement. bBreakdown of the number of observations with the
respective number of systems in each of the sBST components.
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Table 4 are generally distinct, the ranking of the model
scores, which essentially defines the estimated
AUC values, would not differ greatly if the coefficients
varied somewhat. Thus the problem of optimism of the
estimates, because they are evaluated on the same
data as are used to define the models, is also not a
major concern. For example, a calculation of the esti-
mated optimistic bias in the AUC for the BST value of
0.83, using the bootstrap like resampling procedure of
Harrell et al. [17], gives the small value of 0.005.
Nevertheless, this does not negate the value of validating
the observed performance in other observational and clin-
ical trial data sets that may have a different patient mix
(see Discussion).
Discussion
We have devised a data-driven method of representing
the BILAG-2004 index system scores longitudinally from
our large data set of patients. This BST is based on counts
of the number of systems with active/worsening disease
and improving disease. It has a comprehensive form with
six components (BST) and a simplified form (sBST). As
there are several components to the BST and sBST, it is
not as simple as a global score.
Although these tallies seem complex with two different
forms and made up of several components, they are
essentially a simplification of the changes in the nine cat-
egorical system scores of the BILAG-2004 index that is
clinically meaningful and maintains gradation according to
severity. It provides a summary of the number of systems
that have active/worsening disease and those that have
improved between two time points. It is an alternative to
the BILAG-2004 numerical scoring or a global score. A
potential advantage is that drug regimens that induce
more or less improvement (or worsening) in multiple sys-
tems in a group of patients can be distinguished without
requiring disease activity in all systems to change in the
same direction.
The components of sBST can be regarded as the com-
posite outcome of the respective components of the BST,
in similar fashion to the DAS28 score, which is the com-
posite of inflammatory joint counts, ESR and patient’s
visual analogue score. Even though data will be collected
on all components of the tally in clinical studies, not every
component needs to be used in the analysis and different
emphasis can be placed on different components, de-
pending on the question or hypothesis of the study.
Each of the components of the tally can be analysed sep-
arately, and it is anticipated that, in many cases, one or
more of them would be used as the outcome of interest,
rather than all the different components. In a clinical trial it
might be the number of systems with active/worsening
disease over time that would be of interest in the analysis.
The primary outcome of interest could be the difference in
the number of systems with major deterioration over time
between the treatment arms, whereas the secondary out-
comes could be the number of systems with minor deteri-
oration, the number of systems with persistent significant
activity and the composite of the number of systems with
active/worsening disease. In other studies the primary or
initial focus might be on improvements. The choice
between BST and sBST may be application specific or
one or the other may prove to be generally preferred.
The nature of the study and the hypothesis to be
tested will most likely determine whether BST or sBST
should be used in a clinical study. Based on our analysis,
we could not make a recommendation of one over the
other.
As BST and sBST represent measurement of change in
disease activity between two time points, the summation
of the number of systems with active/worsening disease
for patients over time would reflect the burden of disease
activity during the period of study. If the time intervals
between visits are equal or have little variation across pa-
tients in the study, this summation of the number of sys-
tems with active/worsening disease over the study period
may be considered similar to an AUC-type measure.
Although calculation of the AUC is an attractive form of
analysis, caution should be exercised, as there may be
difficulty in its interpretation, especially when the interval
between assessments is prolonged (particularly >3
months apart), and if the intervals are variable (as in ob-
servational studies). An alternative, and more flexible, ana-
lysis of the number of active/worsening systems for two
groups of patients could be based on ordinal regression
models. Ordinal regression of this outcome could be per-
formed at a specified time point or longitudinally. One ap-
proach to the latter is to use a generalized linear mixed
model with random patient effects and a complementary
log-log link. Further advantages of a regression approach
is that the analysis can be stratified on relevant entry char-
acteristics, such as disease activity levels, and patients
with partially missing data can contribute to the analysis.
In addition, patterns of disease activity over time can be
investigated.
In essence, BST and sBST combine the flexibility and
simplicity of numerical scoring with the clinical intuitive-
ness and meaningfulness of the original BILAG-2004
index categorical score. Specifically, this new scheme
does not involve dichotomization of the outcome,
hence it does not suffer from the loss of efficiency asso-
ciated with reliance on a simple yes/no response [9].
Greater efficiency in the detection of group differences
means that fewer patients will be required in comparative
studies, and this will reduce the cost of running such
studies. Thus, in our opinion, this new scheme is a
better and more efficient way of reporting differences in
efficacy between treatment arms in clinical trials as com-
pared with the dichotomous variables that are currently
being used most frequently.
The main limitation of this exploratory analysis is that
the BST and sBST are derived and assessed using the
same data set. Further work will require assessment
using an independent data set and validation of its use
in clinical trials.
In conclusion, the BST represents a new method
of representing the BILAG-2004 system scores
longitudinally.
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Rheumatology key messages
. The BST and sBST provide alternative approaches
to representing BILAG-2004 disease activity
longitudinally.
. The BST and sBST combine the flexibility and sim-
plicity of numerical scoring with the clinical intuitive-
ness of the BILAG-2004 score.
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